Who
Christopher P. Kiritsy
Director
Company insider
Files Form 4 as: Director, Palvella Therapeutics; Director, Htg Molecular Diagnostics.
In numbers
- Trades disclosed
- 27
- Buys
- 2
- Sells
- 1
- Bought
- $34K
- Sold
- $98K
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 20 Sep 2016
- Last trade
- 2 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 4 Sep 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Code M | $40K313 at $127.20 | filing |
| 2 Sep 2026filed 4 Sep 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Sold | $49K313 at $157.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —313 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —313 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Code M | $40K313 at $127.20 | filing |
| 2 Sep 2026filed 4 Sep 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Sold | $49K313 at $157.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 10 Jun 2025filed 11 Jun 2025 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,350 at $0.00 | filing |
| 13 Dec 2024filed 17 Dec 2024 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,700 at $0.00 | filing |
| 2 Dec 2024filed 9 Dec 2024 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500 at $0.00 | filing |
| 21 Jun 2023filed 23 Jun 2023 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 25 May 2023filed 30 May 2023 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Bought | $8,50010,000 at $0.85 | filing |
| 15 Sep 2022filed 15 Sep 2022 | Htg Molecular Diagnosticsoption or derivative | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 27 Jan 2022filed 31 Jan 2022 | Htg Molecular Diagnosticsoption or derivative | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 25 Jun 2021filed 29 Jun 2021 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 23 Jun 2020filed 25 Jun 2020 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 23 Jun 2020filed 25 Jun 2020 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 25 Jan 2020filed 28 Jan 2020 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
Palvella Therapeutics, Inc. (PVLA) – What Are Investment Firms Thinking About This Stock?PVLA · dailypolitical.com · 21 Oct 2026Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) Director Sells $1,758,290.88 in StockPVLA · tickerreport.com · 17 Oct 2026Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual ConferencePVLA · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Christopher P. Kiritsy; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.